研发团队
R&D TEAM
Tianji has an professional and experienced R&D team with a number of PhD as technical leaders with full research background(Pharmaceutical Chemistry, Organic Chemistry, Analytical Chemistry, Pharmacy, Biochemical Technology etc.). The core team has been deeply engaged in the peptide field for nearly 20 years. It is a domestic well-known peptide and small molecule drug development enterprise. In 2019, Tianji R&D lab became Jiangsu Engineering Technology Research Center.
The R&D center is currently conducting technical cooperation projects with Peking University Cancer Hospital, Xijing Hospital, China Pharmaceutical University, and other domestic and foreign scientific research institutions and biomedical companies. In recent years, the annual R&D investment has increased year by years, promoting the company's sustainable innovation and development.
设备设施
EQUIPMENT & FACILITY
Our modern R&D laboratory center spans over 2,000 m², featuring more than 20 standardized labs across peptide synthesis, organic synthesis, sample purification, analytical testing, and formulation development — all supported by a kilogram-scale pilot plant capable of full coverage from lab-scale to pilot-scale studies.
We are equipped with multiple large-scale solid-phase peptide synthesizers, preparative reversed-phase chromatography systems, rotary evaporators, and freeze-dryers (lyophilizers). Our analytical instrumentation includes high-end systems from Agilent and Thermo Fisher — LC-MS, UPLC, GC, fully automated dissolution testers, FT-IR spectrometers, and elemental analyzers — enabling comprehensive quality research, impurity profiling, and analytical method development and validation for raw materials, intermediates, and finished drug products with precision and reliability.
All API and formulation workshops at our new manufacturing campus are built to GMP standards, featuring automated peptide synthesis systems, large-scale purification lines, aseptic freeze-drying lines, and fully automated filling lines for injectables. A dedicated QC center, equipped with comprehensive physicochemical testing, microbial limit, and sterility testing labs, ensures end-to-end quality control from raw material incoming inspection to in-process control and final product release.
This fully integrated infrastructure supports everything from process development and sample preparation to pilot-scale batches and commercial production — serving both our internal pipeline progression and external customer projects. For partners seeking custom peptide synthesis or CRO, CMO, and CDMO services, we offer full equipment and platform capabilities from lab-scale through commercial-scale manufacturing.
设备设施
EQUIPMENT & FACILITY
科技成果
ACHIEMENTS
Leveraging provincial-level innovation platform — the Jiangsu Provincial Enterprise Technology Center — Suzhou Tianji Biopharma has consistently focused on advancing key peptide technologies. We have developed multiple proprietary core technologies across peptide synthesis, high-resolution purification, impurity control, and formulation stability, with numerous R&D outcomes successfully translated into commercial applications.
Intellectual Property: We hold nearly 100 national invention patents covering novel peptide synthesis processes, impurity control technologies, formulation compositions, and intermediate preparation methods — providing robust IP protection for our products and technical services.
Regulatory Approvals: We have secured dozens of API and formulation drug registration approvals across multiple dosage forms, including small-volume injections, lyophilized powders, oral solid dosage forms, and topical preparations, with multiple products having completed generic drug consistency evaIuation. Our peptide APIs — including Tirzepatide and Thymalfasin — have received regulatory recognition from overseas health authorities, while formulations such as Carbetocin Injection have been approved for marketing in international markets.
Pipeline Achievements: We have successfully completed the R&D and filing of multiple peptide formulations and APIs, with several products now on the market. Our active pipeline includes more than 30 innovative and generic drug programs across frontier areas — GLP-1 receptor agonists, and oral cyclic peptides — with select innovative candidates now in clinical-stage development.
Technical Service Track Record: As a CRO/CMO/CDMO service provider, we have successfully completed multiple drug development projects on a contract basis, supporting partner organizations in achieving clinical trial applications. Our capabilities extend to custom synthesis of protected amino acids, specialty peptides, and pharmaceutical excipients, with a proven track record of process development and technology transfer projects.
